HCC at deep and complex sites (adjacent to major blood vessels)
Conditions
Interventions
PRFA group:CT or Ultrasound-guided percutaneous radiofrequency ablation performed in patinets with HCC
hepatectomy group:CT or Ultrasound-guided percutaneous radiofrequency
Sponsors
Eastern Hepatobiliary Surgery Hospital, Second Military Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients with HCC in accordance with the clinical diagnostic criteria of HCC passed at the Chinese Eighth National Live Cancer Academic Conference. Patients with HCC should be confirmed by pathology. There is at least one measurable lesion; 2. Hepatoma involved in this research at complex site is located at the eighth segment of liver, the substantial depth of liver below hepatic integument adjacent to the trunk of inferior vena cava, hepatic vein and portal vein. The tumour is located at hepatic caudate lobe. The maximal diameter < or=3m, AJCC/UICC—TNM stage is stage II and above. Lesions are determined by three senior hepatobiliary experts independently, therefore radical resection is possible. There is no possibility of extra-hepatic metastasis and tumour thrombus of portal vein, hepatic vein, vena cava and bile duct; 3. Criteria of liver function: Child A level, serum bilirubin <=1.5 times the upper limit of normal value, alanine aminotransferase and aspartate aminotransferase <=2 times the upper limit of normal value. It's appropriate to perform liver resection and minimally invasive treatment; 4. No dysfunction in major organs; Blood routine, kidney function, cardiac function and lung function are basically normal; 5. Patients who can understand this trial, male or female, aged 18-70 voluntarily participate in clinical trials and have signed information consent.
Exclusion criteria
Exclusion criteria: 1. Patients with apparent cardiac, pulmonary, cerebric and renal dysfunction, which may affect the treatment of liver cancer; 2. Patients with other diseases which may affect the treatment mentioned here; 3. Patients with medical history of other malignant tumours; 4. Subjects participating in other clinical trials; 5. Women in pregnancy and breast-feeding; 6. Patients with tumour AJCC/UICC—TNM stage at IIIA period or below.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| tumor recurrence rate, disease free survival rate,; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival rate in one, three or five years;disease free survival rate in one, three or five year; | — |
Countries
China
Contacts
Public ContactLehua Shi
Outcome results
None listed